CARGO Therapeutics, Inc. Common Stock
NASDAQ: CRGX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Anup Radhakrishnan
- Employees
- 167
- Headquarters
- San Mateo, United States
- IPO year
- 2023
- Market cap
- $216.2M
- Website
- https://cargo-tx.com
Loading CRGX…
Loading profile data…Frequently asked questions about CRGX
What does CARGO Therapeutics, Inc. Common Stock (CRGX) do?
CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering innovative chimeric antigen receptor (CAR) T-cell therapies for patients battling cancer. Its primary therapeutic candidate is CRG-022, an autologous CD22 CAR T-cell product. This therapy is specifically engineered to counteract mechanisms of resistanc...
Where does CRGX trade?
CARGO Therapeutics, Inc. Common Stock (CRGX) trades on the NASDAQ Global Select.
What sector is CRGX in?
CARGO Therapeutics, Inc. Common Stock (CRGX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of CARGO Therapeutics, Inc. Common Stock?
Anup Radhakrishnan is the chief executive officer of CARGO Therapeutics, Inc. Common Stock (CRGX).
Where is CARGO Therapeutics, Inc. Common Stock headquartered?
CARGO Therapeutics, Inc. Common Stock is headquartered in United States.
Does CRGX pay a dividend?
CARGO Therapeutics, Inc. Common Stock (CRGX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CRGX go public?
CARGO Therapeutics, Inc. Common Stock (CRGX) completed its initial public offering in 2023.